Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections

@article{Farinholt2021TransmissionEO,
  title={Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections},
  author={Timothy Farinholt and Harshavardhan Doddapaneni and Xiang Qin and Vipin Menon and Qingchang Meng and Ginger A Metcalf and Hsu Chao and Marie-Claude Gingras and Paige Farinholt and Charu Agrawal and Donna M. Muzny and Pedro A. Piedra and Richard A. Gibbs and Joseph F Petrosino},
  journal={medRxiv},
  year={2021}
}
Importance: Vaccine breakthrough by an emergent SARS-CoV-2 variant poses a great risk to global public health. Objective: To determine the SARS-CoV-2 variant responsible for 6 cases of vaccine breakthrough. Design: Nasopharyngeal swabs from suspected vaccine breakthrough cases were tested for SARS-CoV-2 by qPCR for Wuhan-Hu1 and Alpha variant. Positive samples were then sequenced by Swift Normalase Amplicon Panels to determine the causal variant. Setting: Transmission event occurred at events… Expand
An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam
TLDR
Breakthrough Delta variant infections following Oxford-AstraZeneca vaccination may cause asymptomatic or mild disease, but are associated with high viral loads, prolonged PCR positivity and low levels of vaccine-induced neutralizing antibodies. Expand
Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients
  • Xufang Deng, M. Evdokimova, +6 authors Susan C Baker
  • Medicine
  • Viruses
  • 2021
TLDR
The results highlight the high viral load that can occur in asymptomatic breakthrough infections and the vulnerability of immunosuppressed individuals to post-vaccination infections by diverse variants of SARS-CoV-2. Expand
SARS-CoV-2 Delta vaccine breakthrough transmissibility in Alachua, Florida
TLDR
Delta infection transmissibility and general VL patterns in vaccinated individuals suggest limited levels of sterilizing immunity that need to be considered by public health policies, and ongoing evaluation of vaccine boosters should address whether extra vaccine doses might curb breakthrough contribution to epidemic spread. Expand
SARS-CoV-2 variants associated with vaccine breakthrough in the Delaware Valley through summer 2021
TLDR
A detailed picture of viral evolution in the Delaware Valley and a geographically matched analysis of vaccine breakthroughs is provided and a rigorous statistical approach to interrogating enrichment of viral variants is introduced. Expand
Epidemiology Features and Effectiveness of Vaccination and Non-Pharmaceutical Interventions of Delta and Lambda SARS-CoV-2 Variants
  • Wenqing Bai, Yue Gu, Haoliang Liu, Lei Zhou
  • Medicine
  • China CDC Weekly
  • 2021
As the epidemic time of COVID-19 outbreaks worldwide has extended and the range of prevalence has expanded, SARS-CoV-2 viruses have continuously evolved and mutated, and multiple virus variants haveExpand
Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants
TLDR
All SARS-CoV-2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2 (APN01), providing proof of principle of a pan-SARS- CoV- 2 therapeutic. Expand
Increased neutralization of SARS-CoV-2 Delta variant by nanobody (Nb22) and the structural basis
TLDR
Nb22-Fc, among the previously reported nanobodies, exhibited 8.4-fold increased neutralization potency against Delta variant with an IC50 value of 0.41 ng/ml (5.13 pM) relative to Alpha variant, and crystal structural analysis reveals that Nb22 on SARS-CoV-2 RBD effectively blocks the binding of RBD to ACE2 during virus infection. Expand
Limited impact of Delta variant’s mutations in the effectiveness of neutralization conferred by natural infection or COVID-19 vaccines in a Latino population
TLDR
Healthy vaccinated individuals showed a limited breadth of neutralization against the Delta and Epsilon variants of the SARS-CoV-2 pandemic, but no clear evidence suggests it has increased virulence. Expand
A Push for Real Normal: Mass Screening for COVID-19
  • L. Poon
  • Medicine
  • Clinical chemistry
  • 2021
TLDR
Hong Kong exemplifies the potential use of NAATs for controlling infectious disease and provides accurate and timely laboratory diagnostic test results to public health experts and other stakeholders in a robust manner, in sharp contrast to the last influenza pandemic in 2009. Expand
How the unvaccinated threaten the vaccinated for COVID-19: A Darwinian perspective
TLDR
Describing yet another variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, this one originating in Brazil, suggests that vaccines currently available are still expected to provide protection against this variant. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 27 REFERENCES
SARS-CoV-2 variants, spike mutations and immune escape
TLDR
The literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, is summarized, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discussed in the context of observed mutation frequencies in global sequence datasets. Expand
Genomic epidemiology of SARS-CoV-2 in the United Arab Emirates reveals novel virus mutation, patterns of co-infection and tissue specific host responses
TLDR
The genomic epidemiological and molecular biological knowledge obtained in the study provides new insights for the SARS-CoV-2 evolution and transmission and highlights the importance of sustained surveillance of the virus mutation using genomic sequencing as a public health strategy. Expand
Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
TLDR
After 2 doses of either vaccine there were only modest differences in vaccine effectiveness with the B.1. Expand
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
TLDR
The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms. Expand
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
TLDR
A rational and dynamic virus nomenclature that uses a phylogenetic framework to identify those lineages that contribute most to active spread and is designed to provide a real-time bird’s-eye view of the diversity of the hundreds of thousands of genome sequences collected worldwide. Expand
The D614G mutation in the SARS-CoV2 Spike protein increases infectivity in an ACE2 receptor dependent manner.
  • Junko Ogawa, Wei Zhu, +4 authors G. Pao
  • Biology, Medicine
  • bioRxiv : the preprint server for biology
  • 2020
TLDR
Using a SARS-CoV2 Spike protein pseudotyped lentiviral vector, it is observed that the D614G variant Spike has >1/2 log10 increased infectivity in human cells expressing the human ACE2 protein as the viral receptor. Expand
Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2
TLDR
This review comprehensively addresses in detail the variations in S protein, its receptor-binding characteristics and detailed structural interactions, the process of cleavage involved in priming, as well as other differences between coronaviruses. Expand
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
TLDR
It is demonstrating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination, and it is shown that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of Sars- coV- 2 S and SARS S bind with similar affinities to human ACE2, correlating with the efficient spread of SATS among humans. Expand
Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention
TLDR
This study found that the vaccine has to have an efficacy of at least 70% to prevent an epidemic and at least 80% to largely extinguish an epidemic without any other measures (e.g., social distancing). Expand
Coronapp: A web application to annotate and monitor SARS‐CoV‐2 mutations
TLDR
This work presents a webtool, coronapp, dedicated to easily processing user‐provided SARS‐CoV‐2 genomic sequences and visualizing the current worldwide status of Sars‐Co V‐2 mutations. Expand
...
1
2
3
...